Alnylam to Host Tenth “RNAi Roundtable” Webcast Series

Key Takeaways

• Alnylam launches 10th RNAi Roundtable series in 2026
• Webinars will cover bleeding disorders, hypertension, Huntington's disease
• Pipeline aims to exceed 40 clinical programs by 2030
• AI integration accelerates RNAi discovery and delivery platforms
• Live streams on investors.alnylam.com with replay within three hours

Pulse Analysis

Alnylam Pharmaceuticals, the pioneer of RNA interference therapeutics, is leveraging its investor‑focused communication platform to host the tenth installment of its “RNAi Roundtable” webcast series. The live events, streamed from the company’s investor portal and archived within three hours, give analysts, partners and clinicians direct access to the latest data from Alnylam’s research teams. By opening a window onto its discovery pipeline, the roundtables reinforce transparency, build confidence in the firm’s scientific leadership, and differentiate Alnylam in a crowded biotech landscape where stakeholder engagement is increasingly digital.

The 2026 schedule spotlights three high‑impact candidates. ALN‑6400 targets plasminogen to treat a broad spectrum of bleeding disorders, a market estimated at billions of dollars globally. Zilebesiran, an angiotensinogen‑silencing therapy, promises continuous blood‑pressure control, potentially reshaping hypertension management. ALN‑HTT02 aims at exon‑1 of the huntingtin gene, offering a disease‑modifying approach for Huntington’s disease, a condition with no curative options. Each program illustrates Alnylam’s expanding tissue‑targeting capabilities and its ambition to move RNAi beyond rare diseases into more prevalent therapeutic areas.

These webinars dovetail with Alnylam’s “Alnylam 2030” roadmap, which targets more than 40 clinical programs by the end of the decade and a deeper penetration into new tissues through artificial‑intelligence‑driven design. The AI‑enhanced discovery platform shortens pre‑clinical cycles, a competitive edge as peers race to commercialize gene‑silencing drugs. For investors, the roundtables provide timely insight into milestone timelines, regulatory pathways, and partnership opportunities with giants such as Roche and Novartis. As the RNAi market is projected to surpass $10 billion by 2035, Alnylam’s transparent outreach could translate into stronger market positioning and valuation upside.